Bayer HealthCare announced today that the oral anticoagulant Xarelto® (rivaroxaban), used as a single drug intervention, was as effective and safe as the current dual drug approach of subcutaneous enoxaparin followed by Vitamin K antagonist (VKA), in treating patients with acute symptomatic pulmonary embolism (PE) and preventing them from developing a secondary venous thromboembolism (VTE).
http://www.hospitalpharmacyeurope.com/default.asp?title=Xarelto_single_pill_beats_enoxaparin%2C_VKA_combo&page=article.display&article.id=28417
http://www.hospitalpharmacyeurope.com/default.asp?title=Xarelto_single_pill_beats_enoxaparin%2C_VKA_combo&page=article.display&article.id=28417
No comments:
Post a Comment